Portolan Capital Management Increases Stake in Health Catalyst

Summary

Portolan Capital Management LLC increased its stake in Health Catalyst, Inc. (NASDAQ:HCAT) by 12.9% during the fourth quarter, now holding 749,029 shares valued at $5.3 million. Analysts have mixed ratings for HCAT, with an average target price of $8.73. Reports indicate insider selling by COO Daniel Lesueur at $4.52 per share. HCAT’s stock opened at $3.93, with a market cap of $275.93 million and a 52-week range of $3.60 to $9.24.Market Beat Other institutional investors, including Impax Asset Management and Geode Capital Management, have also adjusted their holdings in Health Catalyst.Market Beat+ 2

Impact Analysis

This event is primarily at the company level, focusing on Health Catalyst (HCAT). The increased investment by Portolan Capital Management and other institutional investors suggests confidence in HCAT’s future performance, potentially influencing stock price positively. However, insider selling by the COO might signal caution, which could counterbalance investor optimism.Market Beat The stock’s current price and analysts’ target suggest potential upside, but risks include market volatility and investor sentiment shifts.Market Beat+ 2 Opportunities may exist for value investors seeking entry points at lower stock prices, considering the 52-week range and institutional interest.